RAPT Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€0.00 - Cost of goods sold
€171.60K - Gross profit
-€171.60K - SG&A expenses
€24.60M - R&D expenses
€72.22M - EBITDA
-€94.49M - D&A
€888.89K - EBIT
-€97.00M - Interest expenses
€0.00 - EBT
-€91.37M - Tax expenses
€0.00 - Net income
-€91.37M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€33.00M - Changes in working capital
€29.00M - Operating cash flow
-€78.72M - Capex
€86.66K - Other investing cash flow
€0.00 - Net investing cash flow
-€40.09M - Total cash dividends paid
€0.00 - Issuance of common stock
€122.86M - Debt repayment
€0.00 - Other financing cash flow
€66.07K - Net financing cash flow
€122.93M - Foreign exchange effects
€0.00 - Net change in cash
€4.13M - Cash at end of period
€35.94M - Free cash flow
-€78.63M
Balance sheet
- Cash and cash equivalents
€35.94M - Cash and short-term investments
€144.96M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€3.36M - Total current assets
€148.31M - Property, plant & equipment
€2.81M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€1.95M - Total non-current assets
€4.76M - Total assets
€153.08M - Accounts payable
€3.59M - Short-term debt
€1.89M - Other current liabilities
€5.70M - Total current liabilities
€11.19M - Long-term debt
€1.65M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€822.82K - Total liabilities
€12.01M - Common stock
€11.15K - Retained earnings
-€557.15M - Other equity
€13.73K - Total equity
€141.06M - Total liabilities and shareholders' equity
€153.08M
Company information
- Market capitalization
€162.72M - Employees
67 - Enterprise Value
€89.10M
Company ratios
- Gross margin
-
0.0% - EBITDA margin
-
0.0% - EBIT margin
-
0.0% - EBT margin
-
0.0% - Net margin
-
0.0% - ROE
-
-64.8% Much worse than peer group: 23.5% - ROA
-
-59.7% Much worse than peer group: -36.7% - Asset turnover
-
0.0% - FCF margin
-
0.0% - FCF yield
-48.4% - Efficiency ratio
0.0% - Net sales per employee
-
€0.00 - Net income per employee
-
-€1.36M